BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease

T. Foltynie, B. Cheeran, C. H. Williams-Gray, M. J. Edwards, S. A. Schneider, Daniel Weinberger, J. C. Rothwell, R. A. Barker, K. P. Bhatia

Research output: Contribution to journalArticle

Abstract

Background: Levodopa induced dyskinesias (LID) are a common problem which ultimately limit the effective treatment of patients with Parkinson's disease (PD). There is accumulating evidence that LID develop due to abnormal synaptic plasticity, which is in turn influenced by the release of brain derived neurotrophic factor (BDNF). Methods: The influence of a common functional polymorphism of the BDNF gene on the risk of developing dyskinesias in a large cohort of patients with PD (n = 315), who were independently and variably treated with levodopa and/or other dopaminergic treatments, was investigated. Results: Patients with the met allele of BDNF, associated with lower activity dependent secretion of BDNF, were at significantly higher risk of developing dyskinesias earlier in the course of treatment with dopaminergic agents (hazard ratio for each additional met allele 2.12, p = 0.001), which persisted following adjustment for potential confounding variables. Conclusion: This functional polymorphism may help predict which individuals are most at risk of LID and is consistent with the known actions of BDNF on synaptic plasticity in the striatum.

Original languageEnglish (US)
Pages (from-to)141-144
Number of pages4
JournalJournal of Neurology, Neurosurgery and Psychiatry
Volume80
Issue number2
DOIs
StatePublished - Feb 2009
Externally publishedYes

Fingerprint

Brain-Derived Neurotrophic Factor
Dyskinesias
Levodopa
Parkinson Disease
Neuronal Plasticity
Alleles
Dopamine Agents
Confounding Factors (Epidemiology)
Therapeutics
Genes

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Surgery
  • Medicine(all)

Cite this

BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease. / Foltynie, T.; Cheeran, B.; Williams-Gray, C. H.; Edwards, M. J.; Schneider, S. A.; Weinberger, Daniel; Rothwell, J. C.; Barker, R. A.; Bhatia, K. P.

In: Journal of Neurology, Neurosurgery and Psychiatry, Vol. 80, No. 2, 02.2009, p. 141-144.

Research output: Contribution to journalArticle

Foltynie, T, Cheeran, B, Williams-Gray, CH, Edwards, MJ, Schneider, SA, Weinberger, D, Rothwell, JC, Barker, RA & Bhatia, KP 2009, 'BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease', Journal of Neurology, Neurosurgery and Psychiatry, vol. 80, no. 2, pp. 141-144. https://doi.org/10.1136/jnnp.2008.154294
Foltynie, T. ; Cheeran, B. ; Williams-Gray, C. H. ; Edwards, M. J. ; Schneider, S. A. ; Weinberger, Daniel ; Rothwell, J. C. ; Barker, R. A. ; Bhatia, K. P. / BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease. In: Journal of Neurology, Neurosurgery and Psychiatry. 2009 ; Vol. 80, No. 2. pp. 141-144.
@article{90716a802989479bbea119016189dc0d,
title = "BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease",
abstract = "Background: Levodopa induced dyskinesias (LID) are a common problem which ultimately limit the effective treatment of patients with Parkinson's disease (PD). There is accumulating evidence that LID develop due to abnormal synaptic plasticity, which is in turn influenced by the release of brain derived neurotrophic factor (BDNF). Methods: The influence of a common functional polymorphism of the BDNF gene on the risk of developing dyskinesias in a large cohort of patients with PD (n = 315), who were independently and variably treated with levodopa and/or other dopaminergic treatments, was investigated. Results: Patients with the met allele of BDNF, associated with lower activity dependent secretion of BDNF, were at significantly higher risk of developing dyskinesias earlier in the course of treatment with dopaminergic agents (hazard ratio for each additional met allele 2.12, p = 0.001), which persisted following adjustment for potential confounding variables. Conclusion: This functional polymorphism may help predict which individuals are most at risk of LID and is consistent with the known actions of BDNF on synaptic plasticity in the striatum.",
author = "T. Foltynie and B. Cheeran and Williams-Gray, {C. H.} and Edwards, {M. J.} and Schneider, {S. A.} and Daniel Weinberger and Rothwell, {J. C.} and Barker, {R. A.} and Bhatia, {K. P.}",
year = "2009",
month = "2",
doi = "10.1136/jnnp.2008.154294",
language = "English (US)",
volume = "80",
pages = "141--144",
journal = "Journal of Neurology, Neurosurgery and Psychiatry",
issn = "0022-3050",
publisher = "BMJ Publishing Group",
number = "2",

}

TY - JOUR

T1 - BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease

AU - Foltynie, T.

AU - Cheeran, B.

AU - Williams-Gray, C. H.

AU - Edwards, M. J.

AU - Schneider, S. A.

AU - Weinberger, Daniel

AU - Rothwell, J. C.

AU - Barker, R. A.

AU - Bhatia, K. P.

PY - 2009/2

Y1 - 2009/2

N2 - Background: Levodopa induced dyskinesias (LID) are a common problem which ultimately limit the effective treatment of patients with Parkinson's disease (PD). There is accumulating evidence that LID develop due to abnormal synaptic plasticity, which is in turn influenced by the release of brain derived neurotrophic factor (BDNF). Methods: The influence of a common functional polymorphism of the BDNF gene on the risk of developing dyskinesias in a large cohort of patients with PD (n = 315), who were independently and variably treated with levodopa and/or other dopaminergic treatments, was investigated. Results: Patients with the met allele of BDNF, associated with lower activity dependent secretion of BDNF, were at significantly higher risk of developing dyskinesias earlier in the course of treatment with dopaminergic agents (hazard ratio for each additional met allele 2.12, p = 0.001), which persisted following adjustment for potential confounding variables. Conclusion: This functional polymorphism may help predict which individuals are most at risk of LID and is consistent with the known actions of BDNF on synaptic plasticity in the striatum.

AB - Background: Levodopa induced dyskinesias (LID) are a common problem which ultimately limit the effective treatment of patients with Parkinson's disease (PD). There is accumulating evidence that LID develop due to abnormal synaptic plasticity, which is in turn influenced by the release of brain derived neurotrophic factor (BDNF). Methods: The influence of a common functional polymorphism of the BDNF gene on the risk of developing dyskinesias in a large cohort of patients with PD (n = 315), who were independently and variably treated with levodopa and/or other dopaminergic treatments, was investigated. Results: Patients with the met allele of BDNF, associated with lower activity dependent secretion of BDNF, were at significantly higher risk of developing dyskinesias earlier in the course of treatment with dopaminergic agents (hazard ratio for each additional met allele 2.12, p = 0.001), which persisted following adjustment for potential confounding variables. Conclusion: This functional polymorphism may help predict which individuals are most at risk of LID and is consistent with the known actions of BDNF on synaptic plasticity in the striatum.

UR - http://www.scopus.com/inward/record.url?scp=60249103437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60249103437&partnerID=8YFLogxK

U2 - 10.1136/jnnp.2008.154294

DO - 10.1136/jnnp.2008.154294

M3 - Article

C2 - 18977816

AN - SCOPUS:60249103437

VL - 80

SP - 141

EP - 144

JO - Journal of Neurology, Neurosurgery and Psychiatry

JF - Journal of Neurology, Neurosurgery and Psychiatry

SN - 0022-3050

IS - 2

ER -